Repatha OK'd; Payers Eye PCSK9 Rebate/Discount War

Seeking to stay ahead of the other proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor on the US market, Amgen said it was pricing its newly approved drug Repatha (evolocumab) at $14,100 per year – $500 below Sanofi's and Regeneron Pharmaceuticals' Praluent (alirocumab), whose annual cost is $14,600.